Matches in SemOpenAlex for { <https://semopenalex.org/work/W3081206991> ?p ?o ?g. }
Showing items 1 to 84 of
84
with 100 items per page.
- W3081206991 abstract "2567 Background: The prognosis of pancreatic cancer patients is one of the most dismal of all cancers. Gemcitabine is a potent anticancer drug for pancreatic cancer, however, one should consider that the clinical benefit of anticancer drugs is limited and other potent therapeutic tool is eagerly awaited. Vascular endothelial growth factor (VEGF) is a glycoprotein which is predominantly related to the neoplastic angiogenesis. VEGF-receptor 2 (VEGFR2; Flk-1 and KDR) is an essential target for tumor angiogenesis. We first identify the epitope peptides of vascular endothelial growth factor receptor 2 (VEGFR2) and confirmed that stimulation using these peptides induces CTLs with potent cytotoxicity in HLA class I-restricted fashion. Methods: We proceeded to Phase I clinical trial using gemcitabine and one of these peptides. Patients were sequentially allocated to cohorts of 6 patients per group receiving 0.5, 1.0, 2.0mg of peptides/body. No intra-patient dose escalation was permitted. The eligibility criteria are: being aged between 20- and 80- year old, expecting the survival more than 3 months after the initiation of this treatment, adequate organ function including bone marrow function, and having HLA-A*2402 (A24) genotype. The enrolled patients received 4 cycles of VEGFR2 peptide sc. and 3 cycles of 1,000 mg/m2 gemcitabine weekly. Results: No patients had grade 3 and 4 toxicity, and dose escalation was succeeded without any DLT. CTL response was observed in 50%, 67%, and 67% of 0.5mg, 1.0mg, and 2.0mg cohort, respectively. The delayed type hypersensitivity of the peptide-injection site was recognized in 83%, 67%, and 100% of 0.5mg, 1.0mg, and 2.0mg cohort, respectively. Therefore, we concluded that MTD should be 2.0mg of peptide. Disease control rate (>SD) was 67% (12/18 patients), and one patient had PR. The median survival time was 8.72 months. Conclusions: These results are promising to proceed the pivotal clinical trial, and the randomized phase II/III trial will start in 2009. No significant financial relationships to disclose." @default.
- W3081206991 created "2020-09-01" @default.
- W3081206991 creator A5000823360 @default.
- W3081206991 creator A5004211331 @default.
- W3081206991 creator A5005209390 @default.
- W3081206991 creator A5021237761 @default.
- W3081206991 creator A5031330175 @default.
- W3081206991 creator A5040216764 @default.
- W3081206991 creator A5051950705 @default.
- W3081206991 creator A5058284228 @default.
- W3081206991 creator A5073275097 @default.
- W3081206991 date "2009-05-20" @default.
- W3081206991 modified "2023-09-24" @default.
- W3081206991 title "Phase I clinical trial with VEGFR2-epitope peptide and gemcitabine for patients with advanced pancreatic cancer" @default.
- W3081206991 doi "https://doi.org/10.1200/jco.2009.27.15_suppl.2567" @default.
- W3081206991 hasPublicationYear "2009" @default.
- W3081206991 type Work @default.
- W3081206991 sameAs 3081206991 @default.
- W3081206991 citedByCount "0" @default.
- W3081206991 crossrefType "journal-article" @default.
- W3081206991 hasAuthorship W3081206991A5000823360 @default.
- W3081206991 hasAuthorship W3081206991A5004211331 @default.
- W3081206991 hasAuthorship W3081206991A5005209390 @default.
- W3081206991 hasAuthorship W3081206991A5021237761 @default.
- W3081206991 hasAuthorship W3081206991A5031330175 @default.
- W3081206991 hasAuthorship W3081206991A5040216764 @default.
- W3081206991 hasAuthorship W3081206991A5051950705 @default.
- W3081206991 hasAuthorship W3081206991A5058284228 @default.
- W3081206991 hasAuthorship W3081206991A5073275097 @default.
- W3081206991 hasConcept C121608353 @default.
- W3081206991 hasConcept C126322002 @default.
- W3081206991 hasConcept C143998085 @default.
- W3081206991 hasConcept C147483822 @default.
- W3081206991 hasConcept C167734588 @default.
- W3081206991 hasConcept C195616568 @default.
- W3081206991 hasConcept C203014093 @default.
- W3081206991 hasConcept C2777025900 @default.
- W3081206991 hasConcept C2780210213 @default.
- W3081206991 hasConcept C2780258809 @default.
- W3081206991 hasConcept C2780394083 @default.
- W3081206991 hasConcept C502942594 @default.
- W3081206991 hasConcept C535046627 @default.
- W3081206991 hasConcept C71924100 @default.
- W3081206991 hasConceptScore W3081206991C121608353 @default.
- W3081206991 hasConceptScore W3081206991C126322002 @default.
- W3081206991 hasConceptScore W3081206991C143998085 @default.
- W3081206991 hasConceptScore W3081206991C147483822 @default.
- W3081206991 hasConceptScore W3081206991C167734588 @default.
- W3081206991 hasConceptScore W3081206991C195616568 @default.
- W3081206991 hasConceptScore W3081206991C203014093 @default.
- W3081206991 hasConceptScore W3081206991C2777025900 @default.
- W3081206991 hasConceptScore W3081206991C2780210213 @default.
- W3081206991 hasConceptScore W3081206991C2780258809 @default.
- W3081206991 hasConceptScore W3081206991C2780394083 @default.
- W3081206991 hasConceptScore W3081206991C502942594 @default.
- W3081206991 hasConceptScore W3081206991C535046627 @default.
- W3081206991 hasConceptScore W3081206991C71924100 @default.
- W3081206991 hasLocation W30812069911 @default.
- W3081206991 hasOpenAccess W3081206991 @default.
- W3081206991 hasPrimaryLocation W30812069911 @default.
- W3081206991 hasRelatedWork W157457955 @default.
- W3081206991 hasRelatedWork W1978670801 @default.
- W3081206991 hasRelatedWork W1979594711 @default.
- W3081206991 hasRelatedWork W1991568191 @default.
- W3081206991 hasRelatedWork W1993513572 @default.
- W3081206991 hasRelatedWork W1995811812 @default.
- W3081206991 hasRelatedWork W2010992835 @default.
- W3081206991 hasRelatedWork W2018173562 @default.
- W3081206991 hasRelatedWork W2066597463 @default.
- W3081206991 hasRelatedWork W2077595741 @default.
- W3081206991 hasRelatedWork W2106353572 @default.
- W3081206991 hasRelatedWork W2116665727 @default.
- W3081206991 hasRelatedWork W2120220319 @default.
- W3081206991 hasRelatedWork W2167157100 @default.
- W3081206991 hasRelatedWork W2222453260 @default.
- W3081206991 hasRelatedWork W2283064216 @default.
- W3081206991 hasRelatedWork W2605007591 @default.
- W3081206991 hasRelatedWork W279878103 @default.
- W3081206991 hasRelatedWork W2800353792 @default.
- W3081206991 hasRelatedWork W2096066888 @default.
- W3081206991 isParatext "false" @default.
- W3081206991 isRetracted "false" @default.
- W3081206991 magId "3081206991" @default.
- W3081206991 workType "article" @default.